Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies

BACKGROUND: Inappropriate signaling through the epidermal growth factor receptor family (EGFR1/ERBB1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) of receptor tyrosine kinases leads to unregulated activation of multiple downstream signaling pathways that are linked to cancer formation and progression. In...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Souza, Jimson W., Reddy, Smitha, Goldsmith, Lisa E., Shchaveleva, Irina, Marks, James D., Litwin, Samuel, Robinson, Matthew K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227695/
https://www.ncbi.nlm.nih.gov/pubmed/25386657
http://dx.doi.org/10.1371/journal.pone.0112376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227695/
https://www.ncbi.nlm.nih.gov/pubmed/25386657
http://dx.doi.org/10.1371/journal.pone.0112376

Ejemplares similares